Boehringer Ingelheim signed a global deal for a preclinical antibody program from Immunitas Therapeutics, targeting chronic inflammatory and autoimmune diseases. The agreement gives Boehringer full worldwide development, manufacturing, and commercialization rights, with Immunitas eligible for upfront and milestone payments totaling up to $478 million, tied to regulatory and commercial progress.